The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...
Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how the focus of technology development is shifting toward ensuring safety and continuous hearing for children.
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...
Dr. Dina Radenkovic, CEO of Gameto, identifies the main contributors to the gap in in women's health innovation.
Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how the focus of technology development is shifting toward ensuring safety and continuous hearing for children.
Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in ...
Dr. Dina Radenkovic, CEO of Gameto, discusses the key considerations for bringing iPSC-based fertility treatments to market from a regulatory and manufacturing perspective.
Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback